History – celebrating 25 years of R&D

1995

Orexo is founded with a vision to develop improved pharmaceuticals, fulfilling unmet patient needs. This is done by optimization of the properties of well-documented substances in combination with Orexo’s innovative drug delivery technologies.

2000

The company´s first own developed product Diabact® UBT, for diagnosing of the gastric ulcer bacterium Helicobacter pylori, is approved in its first market. More markets will follow and today Diabact® UBT is commercialized worldwide through different partners.

2003

New owners contribute with financing and several development projects are started.

2005

Orexo is listed on the Nasdaq Stockholm stock exchange.

2008

The own developed product Abstral®, for treatment of breakthrough cancer, is approved in its first market. More markets will follow and today the product is commercialized worldwide through different partners.

2009

Orexo´s own developed product for insomnia is approved and is today commercialized by Mylan on multiple markets.

2010

The company issues new shares and Novo A/S enter Orexo as the largest shareholder. With the investment from Novo A/S the Board of Directors reviews the strategy and creates a vision of establishing a commercial business in the US based on Orexo’s proprietary products.

2013

Orexo establishes a commercial subsidiary in the US and launches Zubsolv®, for treatment of Opioid Use Disorder, in September 2013. The launch take place just ten weeks after FDA approval.

2015

Orexo divests its subsidiary Kibion, which also includes the product Diabact® UBT.

2016

After three years in the US, Orexo sells Zubsolv® for more than SEK 480 million and more than SEK 1 000 million gross in total, thereby reaching the first full year in history with profitability.

2018

The company wins a multiyear patent battle against the generic company Teva/Actavis securing patent protection for Zubsolv® in the US until 2032. Shortly thereafter the company internalizes its sales force.

2019

Orexo enters a partnership with GAIA AG, a world leader within digital therapeutics, with the aim to develop a digital therapy for treatment of Opioid Use Disorder.